PTEN and cancer: Together with the previously established post-translational mechanism for PTEN down-regulation through PTEN Tyr336 dephosphorylation, our data further solidified the role of PRL2 as a negative regulator of PTEN, supporting the PTEN augmentation strategy for cancer treatment through targeting PRL2.